Edwards Lifesciences Corporation $EW Shares Sold by Granite Harbor Advisors Inc.

Granite Harbor Advisors Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,748 shares of the medical research company’s stock after selling 241 shares during the quarter. Granite Harbor Advisors Inc.’s holdings in Edwards Lifesciences were worth $371,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $1,760,000. Czech National Bank raised its stake in Edwards Lifesciences by 5.8% during the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares in the last quarter. Mirova US LLC raised its stake in Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after acquiring an additional 9,188 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.9%

Shares of Edwards Lifesciences stock opened at $76.73 on Thursday. The stock’s fifty day moving average is $77.44 and its 200-day moving average is $76.25. The firm has a market capitalization of $45.05 billion, a PE ratio of 11.04, a price-to-earnings-growth ratio of 3.65 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.70 earnings per share. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of several recent analyst reports. Mizuho lifted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.